The silencing of IGF1R or treatment with antibodies binding IGF1 and IGF2, BI836845 or xentuzumab inhibited the growth of in vivo cocultured CAFs-tumor cell xenografts [73]. The gene discussed is IGF2; the disease is neoplasm.